Open AccessBook
Decision Modelling for Health Economic Evaluation
Andrew Briggs,Karl Claxton,Mark Sculpher +2 more
- 17 Aug 2006
2.9K
TL;DR: This book deals with decision modelling techniques that can be used to estimate the value for money of various interventions including medical devices, surgical procedures, diagnostic technologies, and pharmaceuticals.
read more
Abstract: 1. Introduction 2. Key aspects of decision modelling for economic evaluation 3. Further developments in decision analytic models for economic evaluation 4. Making decision models probabilistic 5. Analysing and presenting simulation output from probabilistic models 6. Decision-making, uncertainty and the value of information 7. Efficient research design 8. Future challenges for cost-effectiveness modelling of health care interventions
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Cost‐Effectiveness of Therapeutic Hypothermia to Treat Neonatal Encephalopathy
Dean A. Regier,Stavros Petrou,Jane Henderson,Oya Eddama,Nishma Patel,Brenda Strohm,Peter Brocklehurst,A. David Edwards,Denis Azzopardi +8 more
TL;DR: The probability that cooling is a cost-effective treatment for neonatal encephalopathy is finely balanced over the first 18 months after birth but increases substantially when national incidence data or an extended time horizon are considered.
33
Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature.
TL;DR: Although several studies conclude that DES may be cost effective in large subgroups of patients, under real-world conditions, the cost-effectiveness of DES is unfavourable in comparison with BMS.
33
Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population.
Jennifer Y. Zhou,Danny Liew,Stephen J. Duffy,Stephen J. Duffy,Antony Walton,Nay M. Htun,Dion Stub,Dion Stub +7 more
TL;DR: TAVI is likely to be highly cost-effective compared to SAVR in intermediate-risk patients with severe aortic stenosis from the Australian healthcare system perspective.
33
Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
Olivia M. Dong,Olivia M. Dong,Stephanie B. Wheeler,Gracelyn Cruden,Craig R. Lee,Deepak Voora,Stacie B. Dusetzina,Tim Wiltshire +7 more
TL;DR: Multigene testing for Medicare patients post-PCI for ACS has a higher probability of being cost-effective over 24 months and the lifetime compared with single-gene testing and standard of care and could help optimize medication prescribing to improve patient outcomes.
32